44
including osteosarcoma and other soft tissue sarcomas (1, 2) . In response to genotoxic stress 45 MDM2 undergoes alternative splicing to generate splice variants that are unable to regulate p53 46 expression (3) (4) (5) . This in turn results in the stabilization of p53 and subsequent upregulation of 47 pathways involved in apoptosis and cell cycle arrest (6) (7) (8) . Current targeted therapies to inhibit 48 SRSF2 is a positive regulator of MDM2 alternative splicing
138
In order to assess the role of SRSF2 as a positive regulator or MDM2 alternative splicing 139 we performed overexpression and knockdown experiments. We began by co-transfecting MCF7 140 cells with the MDM2 3-11-12s wild-type minigene along with either LacZ as a negative control, 141 or T7-SRSF2, followed by mock or UV treatment (50J/m 2 UVC).. We observed that transfection 142 of SRSF2 abolished damage-responsive alternative splicing of minigene transcripts under UVC 143 conditions as compared to the negative control ( Figure 3A, B) . Conversely, we treated MCF7 144 7 cells with siRNA against SRSF2 and confirmed its efficient knockdown ( Figure 3C ). We then 145 performed a nested RT-PCR to identify transcripts from the endogenous MDM2 gene. We 146 found that MDM2-ALT1 (3.12) was significantly induced in the absence of any genotoxic stress 147 as compared to no treatment (NT) and control siRNA (CTRL) ( Figure 3D ). These data indicate 148 that SRSF2 expression is required to facilitate inclusion of all MDM2 internal exons (exons 4 149 through 11), not only the penultimate exon 11 as studied in our minigene system. 
153
We hypothesized that SSOs targeting SRSF2 binding sites would occlude SRSF2 154 binding and could therefore be used to induce skipping the internal exons of MDM2. To test this 155 hypothesis, we designed SSOs against each of our identified binding sites ( Figure 4A ). Briefly, 156 we co-transfected the wild-type MDM2 3-11-12s minigene along with SSOs against SRSF2 157 sites for 24 hours in MCF7 cells. RT-PCR of exogenous MDM2 revealed that SSOs against 158 either SRSF2-165 (SSO1) or SRSF2-213 (SSO2, SSO3) site were effective at inducing 159 expression of the exon-excluded product 3.12 under normal conditions compared to non-160 specific SSO (NS-SSO; Figure 4B ). Whereas SSO1 against the first SRSF2 site induced 3.12 161 modestly at a range of concentrations, SSOs 2 and 3 against the second SRSF2 site were far 162 more potent in inducing exon exclusion at all concentrations ( Figure 4C ). These data are 163 consistent with mutation of the SRSF2 binding sites in the MDM2 minigene described above.
164
Decreasing the levels of SRSF2 caused skipping of multiple internal exons of the 165 endogenous MDM2 transcript, generating MDM2-ALT1. We therefore hypothesized that SSOs 166 targeting the SRSF2 binding sites in exon 11 could likewise induce MDM2-ALT1 expression.
167
We transfected either NS-SSO, SSO1, SSO2, or SSO3 into MCF7 or SMS-CTR cells. We then
168
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The copyright holder for this preprint . http://dx.doi.org/10.1101/784256 doi: bioRxiv preprint first posted online Sep. 26, 2019;  SRSF2 Regulates MDM2 Splicing 8 performed a qRT-PCR assay specific for MDM2-ALT1, which targets the splice junction 169 between exons 3 and 12. Consistent with our results with MDM2 3-11-12s minigene we were 170 able to observe a significant increase in expression of MDM2-ALT1 ( Figure 4D ).
171
We assessed the functional impact of SSO treatment on the p53 pathway by examining 172 transcriptional target levels, as well as cell cycle changes. We found that SSOs targeting the 173 second SRSF2 site (SSO2, SSO3) significantly reduced the expression of GADD45A and 174 CDKN1A in MCF7 cells ( Figure 5E ). We also performed cell cycle analysis but did not find any 175 changes in the any phase of the cell cycle between NS-SSO, and SSO1, SSO2, or SSO3-176 transfected MCF7 cells (data not shown). MCF7 cells are ARF null and therefore lack an intact 177 p53 pathway (18), which may explain the lack of induction of p53 in response to MDM2-ALT1 
185
is different than the human MDM2-ALT1 and comprises exons 3, 4, and 12 ( Figure 5A) (3). To 186 determine the conserved regulation of MDM2 splicing by SRSF2 regulation, we generated a 187 mouse minigene that contains the Mdm2 exon 3 as the first exon joined to exon 11 and exon 188 12, as in the human construct. We next examined the sequence of mouse exon 11 to identify 189 mutations that lower the ESE matrix scores for predicted SRSF2 binding sites in the mouse 190 gene. Mutations similar to those we made in the human minigene lowered the predicted binding 191 scores of the ESE in the mouse Mdm2 exon 11 ( Figure 5B ). We then induced the G165T or
192
The copyright holder for this preprint . http://dx.doi.org/10.1101/784256 doi: bioRxiv preprint first posted online Sep. 26, 2019;  SRSF2 Regulates MDM2 Splicing 9 G213A mutations, or both, into the mouse minigene and tested their ability to support Mdm2 193 splicing regulation. Mutations of both the G165T and G213A residues resulted in increased 194 expression of exon 11-excluded product in the absence of genotoxic stress ( Figure 5C , E). As 195 with the MDM2 3-11-12s G213T mutation, the Mdm2 3-11-12s G213A mutation was more 196 potent than the G165T mutation. It should be noted, however, that the mouse minigene does 197 not accumulate increased exon 11 skipping as a result of UV treatment.
198
Because the mouse splice variant, Mdm2-MS2, is comprised of exon 4 spliced directly to 199 exon 12, we wondered if the sequences in Mdm2 exon 4 may be important to achieve regulation 200 in response to damage treatment in the mouse gene. We engineered a second mouse 201 minigene containing exons 4, 11 and 12 and induced these same mutations in an Mdm2 3-11-202 12s minigene to assess in cell culture with and without UV damage. We observed that both 203 G165T and G213A mutations together resulted in an increase of exon skipping under normal 204 conditions ( Figure 5D , F), and were induced by UV treatment. The effects of the G165T and 205 G213A mutations were additive in both the 3-11-12s and 4-11-12s minigene, suggesting that 206 these SRSF2 sites regulate Mdm2 splicing independently. 
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To precisely pinpoint the regulation of SRSF2 on Mdm2 endogenous transcripts we used 211 CRISPR-Cas9 to induce SRSF2 site mutations. We designed Cas9 guide RNAs (gRNAs) to 212 exon 11 of Mdm2 as well as single-stranded oligonucleotide donor (ssODN) repair templates 213 that included the nucleotide mutation at our sites of interest ( Figure 6A ). Our attempts to recover 214 cells with both mutations were unsuccessful, so we designed separate 243 base pair ssODNs 215 that contained a single point mutation, targeting each site independently. Eventually, we
216
The copyright holder for this preprint . http://dx.doi.org/10.1101/784256 doi: bioRxiv preprint first posted online Sep. 26, 2019;  SRSF2 Regulates MDM2 Splicing 10 recovered NIH 3T3 cell lines with the single G165T mutation but were unable to generate cell 217 lines with the G213A mutation. We subjected both control NIH 3T3 cell lines transfected with a 218 control CRISPR plasmid and cells bearing the G165T mutation to a qPCR to specifically detect 219 expression of Mdm2-MS2. We report that cells with the G165T mutation demonstrated a 220 significantly higher amount of Mdm2-MS2 under normal conditions as compared to control cells 221 ( Figure 6B ).
222
To test the effect of Mdm2-MS2 expression on cell proliferation, we seeded wild-type Given that the identified SRSF2 sites flank the previously identified SRSF1 binding site,
235
we wanted to test the dependency of these sites in counterbalancing the activity of the other.
236
We hypothesized that the positive action of the SRSF2 binding is required to overcome the 237 negative splicing function of the SRSF1 binding. We induced the previously published SRSF1 238 mutation together with one or both of the SRSF2 mutations and tested them in our damage-239 inducible cell culture system ( Figure 7A ). We observed that both the SRSF2-G165T and the 240 . CC-BY-NC-ND 4.0 International license It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint . http://dx.doi.org/10.1101/784256 doi: bioRxiv preprint first posted online Sep. 26, 2019;  SRSF2 Regulates MDM2 Splicing 11 SRSF2-G213T mutation were sufficient to overcome the mutation of the SRSF1 sites, and 241 restore the damage induction of exon 11 skipping (where none was seen in SRSF1 mutant 242 minigene). Lastly, when both SRSF2 sites were mutated in the context of the SRSF1 mutant we 243 again observed a significant increase in the level of exon skipping under normal conditions 244 ( Figure 7B and 7C). These data strongly suggest that the regulation of MDM2 alternative 245 splicing by SRSF2 is necessary to counteract the negative effects of SRSF1. These data further 246 suggest that the density of splicing elements and functional redundancy of regulators in this 247 region plays an important role in the alternative splicing of MDM2 since splicing control is 248 maintained in the absence of both the SRSF1 and SRSF2 elements. Furthermore, identification 249 of additional elements will allow improvement of splice altering therapies that could be used to 250 modulate the p53 pathway in cancer.
252

DISCUSSION
253
We identified SRSF2 as a positive splicing factor that promotes the recognition of exon 254 11 of MDM2. We demonstrated that the SRSF2 binding sites are conserved between mouse 255 and human MDM2 exon 11. Furthermore, these sites are sufficient to promote full-length 256 splicing endogenously as splicing is compromised using either the SSOs or CRISPR-Cas9 257 generated mutations. Exon 11 of MDM2 is well-conserved between mouse and human. Both (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
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266
The regulation of SRSF2 is known to be controlled through alternative splicing of its own 267 transcript, as well as posttranslational acetylation and phosphorylation by SRPK1 and SRPK2 268 (21) . Under both normal and UV damage conditions, SRSF2 is localized to nuclear speckles,
269
which are known to be structures where nuclear processing factors are localized, as well as 270 sites of active mRNA transcription (22, 23) . In response to UVC treatment we observed that the 271 expression levels of SRSF2 increased and importantly, that the number of speckles to which 272 SRSF2 is localized are fewer in number and have a larger foci diameter. Additionally, we saw 273 that binding of SRSF2 was decreased in vivo in response to UV treatment. We infer that the 
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12s minigene (black triangles). Sequences and matrix scores for wild-type (WT) and mutant 568 exonic splicing enhancer (ESE) values were predicted by ESEfinder 3.0. Mutations made in the 569 sequence of the MDM2 3-11-12s minigene lowered the predicted matrix score for binding of 570 splicing factor SRSF2. C. MDM2 3-11-12s minigenes were transfected into MCF7, treated with 571 normal (NOR) or UVC conditions, and harvested 24 hours later. SRSF2 site mutants (G165T p 572 = 1.876e-05, G213T p = 1.081e-04, G165T, G213T p = 3.550e-07) displayed elevated 
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